Cancer Treatment A New Era Autologous cellular immunotherapy activated APCs are

Cancer treatment a new era autologous cellular

This preview shows page 46 - 53 out of 65 pages.

Cancer Treatment: A New Era Autologous cellular immunotherapy – activated APCs are reinfused into patient to direct immune cells vs tumor cell (ie: sipuleucel-T) Immune checkpoint inhibitors – “release the brakes” on the immune system (ie: ipilimumab, nivolumab, pembrolizumab) CAR-T therapy – chimeric antigen receptor (CAR) T cells Immunovirus – therapeutic cancer vaccine Future directions – BiTE antibodies, DNA methylation signature, TMEM score, magic wands, IDH2 blockers, proteomics, intraoperative radiation, CRISP-R technology Cancer immunotherapy
Image of page 46
Patient Case #1: PD-1 Inhibitor ED 33yo male with Hodgkins Lymphoma Apr 2011: standard chemo w/ ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) x6 cycles 2 nd line chemo: GDP (gemcitabine, dexamethasone, cisplatin) 2012: autologous stem cell transplant → recurrence Salvage chemo: brentuximab vedotin (Adcetris®) Salvage chemo: GDP, MOPP (mechlorethamine, vincristine, procarbazine, prednisone), bendamustine Dec 2014: allogeneic stem cell transplant → recurrence Now what???
Image of page 47
Immunotherapy: Checkpoint inhibitors Immune system relies on multiple checkpoints to avoid over activation on healthy cells Tumor cells hijack these checkpoints to escape detection CTLA-4 & PD-1 are upregulated on T cell surface in some cancers PD-L1 can be expressed on tumor cells endogenously or induced by association with T cells PD-1:PD-L1 interaction results in T cell suppression (anergy, exhaustion, death) Atkins MB et al. Clinical Care Options slideset 2014.
Image of page 48
NIVOLUMAB PEMBROLIZUMAB IPILIMUMAB Drake CG et al. Nat Rev Clin Onc. 2014;11:24-37.
Image of page 49
Immunotherapy: Checkpoint inhibitors In melanoma, renal cell, & other tumors, PD-L1 expression is associated with more aggressive disease Inhibiting CTLA-4 & PD-1 can “release the brakes” Checkpoint inhibitors don’t attack the tumor, they set the T cells straight Activity powerful enough to work in the CNS – T cells go everywhere Melanoma patients – on MRI, brain mets are surrounded by tons of T cells Atkins MB et al. Clinical Care Options slideset 2014.
Image of page 50
Immunotherapy: Checkpoint blockade Ribas A. N Engl J Med. 2012;366:2517-2519. Priming phase (lymph node) Effector phase (peripheral tissue) T-cell migration Dendritic cell T cell MHC TCR B7 CD28 CTA-4 T cell Cancer cell MHC TCR PD-1 PD-L1 T cell Cancer cell Dendritic cell T cell MH C CD28 B7 CTLA- 4 MH C PD- 1 PD- L1
Image of page 51
Immunotherapy: PD-1 inhibitors Nivolumab (Opdivo®) – FDA approval Melanoma – unresectable or metastatic; single agent or combination with ipilimumab NSCLC – metastatic; with progression on or after platinum-based chemotherapy and EGFR or ALK therapy if EGFR or ALK positive Renal Cell – advanced disease who have received 1 or 2 prior therapies Summary – ORR in patients with advanced NSCLC, melanoma, renal cell carcinoma 65 of 306 patients had ORR (CR or PR) 30 of those 65 (46%) had response evident at first tumor eval (8wks) 42 of those 65 (65%) had response lasting >1yr 35 of those 65 (54%) had response ongoing at time of data analysis Response persisted off the drug Nivolumab pkg insert , Atkins MB et al. Clinical Care Options slideset 2014.
Image of page 52
Image of page 53

You've reached the end of your free preview.

Want to read all 65 pages?

  • Spring '17
  • Mrs.Stanley

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture